METTL3 Inhibitory Compounds for Selective Enzyme Activity Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with METTL3 activity, such as cancer, autoimmune disorders, neurological diseases, infectious diseases, and inflammatory diseases, lack effective inhibitors to target and modulate the enzyme's function.
Innovation Solution
Development of compounds that inhibit METTL3 activity, which are used in pharmaceutical compositions to treat proliferative disorders, autoimmune diseases, neurological diseases, infectious diseases, and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If METTL3 activity is inhibited to treat diseases, then therapeutic benefits are achieved, but cell proliferation and metastasis are reduced
Solution Approach 1:
The patent modifies the chemical structure parameters of inhibitor compounds to achieve selective METTL3 inhibition. By changing molecular parameters such as substituent groups, ring structures, and functional groups in the compound formula (I), the invention optimizes binding affinity to METTL3 while minimizing off-target effects, thereby achieving therapeutic benefits with controlled impact on cell proliferation
Solution Approach 2:
The inhibitor compounds act as intermediary molecules that bind to METTL3 and prevent its interaction with mRNA substrates. These small molecule intermediaries transfer the therapeutic effect by blocking the enzymatic activity of METTL3, which in turn modulates mRNA expression and stability without directly affecting cell proliferation processes
2Reliability
If compounds are developed to inhibit METTL3, then enzyme activity is modulated, but manufacturing complexity increases
Solution Approach 1:
The patent divides the complex inhibitor molecule into modular segments represented by variables in formula (I), where X, Y, Z, and their substituents can be independently optimized. This segmentation allows for systematic synthesis planning, where different building blocks can be combined through standardized reactions to produce various analogs, simplifying the manufacturing process while maintaining enzyme modulation efficacy
Solution Approach 2:
The invention establishes structure-activity relationship parameters that guide compound optimization. By identifying key molecular parameters (such as specific substituent positions, ring sizes, and functional group types) that determine METTL3 binding affinity, the patent enables rational drug design approaches that reduce the need for extensive trial-and-error synthesis, thereby easing manufacturing complexity
Data Source
AI summary
The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z5 (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity 10 is implicated.